🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Advances in the management of diffuse large B-cell lymphoma underscore evolving strategies in first-line and relapsed settings, including antibody-drug conjugates and CAR T-cell therapy. 🔗 ascopost.com/news/may-2025/… #Hematology #Oncology

Timing matters: Delays in surgery may increase mortality risk for certain breast cancer subtypes, underscoring the role of timely intervention in treatment planning. 🔗 ascopost.com/news/march-202… #BreastCancer #Oncology

ASCO and Google Cloud have introduced an AI-powered tool designed to streamline cancer care documentation, with potential to reduce administrative burden and improve workflow. 🔗 ascopost.com/news/may-2025/… #Oncology #HealthIT

New in #PancreaticCancer: Adding tocilizumab to nab-paclitaxel + gemcitabine didn’t meet 6-mo OS goal, but improved 18-mo survival (27.1% vs 7%) and reduced muscle loss. More grade ≥3 AEs noted. #oncology #ASCO ascopost.com/news/may-2025/…

New data highlights the potential of combining lurbinectedin and atezolizumab in extensive-stage small cell lung cancer. Learn how this approach may impact future treatment strategies. #LungCancer #OncologyNews ascopost.com/news/may-2025/…

Zongertinib shows clinical activity and manageable safety in previously treated HER2-mutant NSCLC, according to early-phase data. Trial details highlight its potential role in a difficult-to-treat population. #LungCancer #OncologyResearch ascopost.com/issues/may-25-…

Mark Cuban’s latest move could shift the standard of care in front-line CML treatment. Implications for practice and pricing merit close review. #Oncology #HealthPolicy ascopost.com/news/may-2025/…

Risk-adapted adjuvant therapy in postmenopausal women with early breast cancer shows no added mortality benefit from chemo in low-risk groups—adherence to endocrine therapy remains key. #BreastCancer #Oncology ascopost.com/news/may-2025/…

SBRT showed higher 3-month complete pain response vs conventional RT for bone metastases, with similar toxicity—potential option for select patients. #RadiationOncology #PalliativeCare ascopost.com/news/may-2025/…

A 14-gene molecular assay can help identify patients with early-stage nonsquamous NSCLC who could benefit from adjuvant chemotherapy after surgery. David R. Spigel, MD, FASCO #lungcancer #ASCO25 ascopost.com/news/may-2025/…

Sacituzumab govitecan and pembrolizumab help patients with advanced PD-L1–positive TNBC live longer without cancer progression compared with chemotherapy and pembrolizumab. Sara Tolaney #ASCO25 #BreastCancer ascopost.com/news/may-2025/…

Second-line fam-trastuzumab deruxtecan-nxki can help people with advanced HER2-positive gastric cancers that have grown during first-line treatment live about 3 months longer. Kohei shitara #ASCO25 #GastricCancer ascopost.com/news/may-2025/…

The PROTAC vepdegestrant could extend progression-free survival for people with previously treated ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation. Erika Hamilton, MD #ASCO25 #BreastCancer ascopost.com/news/may-2025/…

A new study is the first to look at trends over time in alcohol-linked cancer mortality across the United States. #ASCO25 #OncologyResearch ascopost.com/news/may-2025/…

Patients with dMMR colon cancer who receive atezolizumab plus adjuvant chemotherapy experience a 50% reduction in disease recurrence or death vs chemotherapy alone. Frank Sinicrope, MD #ASCO25 #ColonCancer ascopost.com/news/june-2025…

Adding nivolumab to chemoradiotherapy after surgery can decrease the chance of recurrence in patients with locally advanced head and neck squamous cell carcinoma. #ASCO25 #HeadNeckCancer ascopost.com/news/june-2025…

A 3-year exercise program initiated soon after adjuvant chemotherapy improves DFS and OS, and patient-reported physical functioning and health-related fitness, in patients with stage III and high-risk stage II colon cancer. #ASCO25 #OncologyResearch ascopost.com/news/june-2025…

Switching to camizetrant if an ESR1 mutation is detected during first-line treatment can help slow cancer growth for patients with HR-positive, HER2-negative advanced breast cancer, research shows. #ASCO25 #BreastCancer ascopost.com/news/june-2025…

New study shows that adding encorafenib + cetuximab to chemotherapy improves survival in patients with BRAF V600E–mutant metastatic colorectal cancer. Promising results for targeted therapy. #ColorectalCancer #BRAF #Oncology #ASCO2025 🔗 ascopost.com/news/may-2025/…

New research suggests certain menopause meds may help prevent invasive breast cancer. A potential shift in risk-benefit discussions for HRT? 🧬 ascopost.com/news/june-2025… #Oncology #BreastCancer